GLP-1 receptor agonists (GLP-1 RAs) are dosed once-daily or once-weekly and are indicated for weight management in those who are overweight (with ≥1 weight-related comorbidity) or obese (specifically, semaglutide and liraglutide) and for improving glycemic control in people with T2D (all marketed GLP-1 RAs) [120,121,122]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.